Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional ...
Afamitresgene-autoleucel is an autologous T-cell immunotherapy designed to target cancer cells in solid tumors expressing melanoma-associated antigen A4. The Food and Drug Administration (FDA) has ...
Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy. The accelerated approval was ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Afamitresgene ...
A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and ...
The Food and Drug Administration granted accelerated approval for Adaptimmune Therapeutics’ cell therapy Tecelra in treating a specific form of cancer. The drug is on track to treat patients with ...
Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan University-led research team has found. The group irradiated ...
Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors Adoptive immunotherapy using tumor-infiltrating lymphocytes ...
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ...
In the sport of sumo, a bout most commonly ends when one competitor is pushed or thrown outside of a ring of straw bales partially buried in clay. New research shows that using a drug as a blocker to ...
Researchers have developed a way to attack synovial sarcoma -- a rare tumor of soft tissues, such as ligaments and muscles -- using an investigational drug that triggers cell death. Researchers at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results